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Objectives We sought to examine the effect of angiotensin receptor blocker (ARB) on the formation of lesions in the aortic
valves of hypercholesterolemic rabbits.
Background Recently, atherosclerosis has been recognized as a mechanism that is responsible for calcific aortic stenosis.
The effect of ARBs might help to prevent aortic stenosis because they have multiple antiatherosclerotic effects.
Methods Male Japanese white rabbits (n  36) were separated as follows: control with chow diet (C) and vehicle (V)
groups, both of which were fed a 1% cholesterol diet for 8 weeks, and an ARB group (A), which was fed a 1%
cholesterol diet for 8 weeks with ARB (olmesartan, 1 mg/kg/day) for the last 4 weeks.
Results This dose of olmesartan did not affect either blood pressure or cholesterol levels. Dietary cholesterol induced
fatty deposition with macrophage accumulation and osteopontin coexpression in valve leaflets, whereas ARB
decreased macrophage accumulation (% area: V, 9.3  0.34; A, 1.4  0.30; p  0.003) and osteopontin ex-
pression (p  0.017). Angiotensin-converting enzyme was also up-regulated in V and decreased by olmesartan
(p  0.015). Immunohistochemistry with anti-CD31 antibody revealed that dietary cholesterol disrupted and
olmesartan preserved endothelial integrity on the lesion-prone aortic side of the valve (% CD31-positive circum-
ference: V, 30  3.7; A, 62  4.8; p  0.003). Numbers of alpha-smooth muscle actin-positive myofibroblasts
were increased in V and decreased by olmesartan (p  0.003). Real-time polymerase chain reaction revealed
that increased amounts of messenger ribonucleic acid for osteoblast-specific transcription factor core binding
factor alpha-1 in V were diminished by olmesartan.
Conclusions Atherosclerotic changes in the aortic valves of rabbits fed with cholesterol were inhibited by ARB, whereas endo-
thelial integrity was preserved and transdifferentiation into myofibroblasts and/or osteoblasts in valve leaflets
was inhibited. (J Am Coll Cardiol 2007;49:1482–9) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.11.043r
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palcific aortic valve stenosis is a common medical condition
n the elderly (1) and it is currently the most common
ndication for valve replacement (2). Accumulating evidence
uggests that the calcific aortic stenosis (AS) disease process
as many similarities to vascular atherosclerosis (3–8). The
revention or retardation of AS progression is evolving but
his has not yet been achieved in the clinical setting. Two
lasses of drugs, namely hydroxymethylglutaryl coenzyme-A
rom the *First Department of Internal Medicine and †Department of Pharmacol-
gy, Osaka Medical College, Takatsuki, Osaka, Japan. This study was supported in
art by the High-Tech Research Program of Osaka Medical College, Osaka, Japan.
his work was partly presented at the 55th Annual Scientific Session of the American
ollege of Cardiology, Atlanta, Georgia, March 11 to 14, 2006, and published in
bstract form ( J Am Coll Cardiol 2006;47 Suppl A:284A).m
Manuscript received August 23, 2006; revised manuscript received November 1,
006, accepted November 23, 2006.eductase inhibitors (statins) and inhibitors of the renin-
ngiotensin system, might be useful because they have
ultiple antiatherosclerotic effects (9,10). Rajammanaan
t al. (11) have reported recently that atorvastatin inhibits
therosclerotic changes of aortic valves in cholesterol-fed
abbit models. Clinical trials of statins for patients with AS
resently are underway (6,12–15).
In addition, the renin-angiotensin system might be involved
n AS progression because angiotensin-converting enzyme
ACE) is up-regulated in human calcific aortic valves (16),
hich raises the possibility that ACE inhibitors or angiotensin
eceptor blocker (ARB) might inhibit AS progression, but no
nimal data and conflicting clinical data have been generated
14,17). The present study tests whether the ARB (olmesartan)
revents atherosclerotic changes in the aortic valves of rabbit
odels fed dietary cholesterol.
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nimal experiments. Thirty-six male Japanese white rab-
its (2.5 to 3.0 kg) were housed at room temperature with
12-h light-dark cycle and provided with tap water ad
ibitum throughout the experimental period. All animal
tudies were performed according to the “Position of the
merican Heart Association on Research Animal Use,”
dopted by The American Heart Association on November
1, 1984, and proceeded with the approval of the Institu-
ional Animal Care and Use Committee of the Osaka
edical College.
After 4 weeks of a normal standard diet, the rabbits were
eparated into 3 groups. The control group (C; n  12)
emained on the normal diet until sacrifice. The olmesartan
A; n  12) and vehicle (V; n  12) groups received a diet
ontaining 1% cholesterol (Oriental Yeast Co., Osaka,
apan) for 8 weeks until sacrifice. Olmesartan (a gift from
ankyo Pharmaceutical Co., Tokyo, Japan) was prepared by
mulsification with carboxymethyl-cellulose in water. The
uspension (1 mg/kg/day of olmesartan) was administered
rally via a gastric tube to the A group during the last 4
eeks. The V group received 1% carboxymethyl-cellulose by
outh via a gastric tube during the last 4 weeks.
Blood pressure was directly measured at the central artery
f the ear using a SURFLO Flash catheter (Terumo,
okyo, Japan) and transducer 30 min before sacrifice. Blood
amples were collected thereafter, and total plasma choles-
erol and triglycerides were measured enzymatically (Sigma-
ldrich Co., St. Louis, Missouri). At the end of the
rotocol, the rabbits were sacrificed by venous injection with
n overdose of sodium pentobarbital.
issue preparation. After sacrifice, the ascending aortic
ection containing the aortic valve was dissected and rinsed
n phosphate-buffered saline. The aortic root was opened
ongitudinally, and one leaflet from each aortic valve dis-
ected with the adjacent aorta was fixed in 4% paraformal-
ehyde in phosphate-buffered saline for 1 h. Thereafter,
amples for histological and immunohistochemical analyses
ere taken vertically through the cusp and sinus near the
enter of the leaflet according to the method of Otto et al.
3), embedded in Tissue-Tek O.C.T. compound (Sakura
inetechnical, Tokyo, Japan), and snap-frozen in liquid
itrogen. The remaining 2 leaflets from each valve were
rozen immediately for mRNA detection.
istological and immunohistochemical staining. Frozen
ections were cut into 3- to 5-m slices and stained with
ematoxylin and eosin as well as Oil red O. Immunohisto-
hemical studies were performed using the following pri-
ary antibodies; a mouse monoclonal antibody against
abbit macrophages (RAM-11, 1:1,000 dilution, DAKO,
arpinteria, California), anti--smooth muscle actin (1A4,
:1,000 dilution, DAKO), osteopontin (1:50 dilution, Santa
ruz Biotechnology, Santa Cruz, California), anti-ACE1:200, Chemicon International, a Millipore Company, remecula, California), anti-
D31 (1:100, DAKO), and an-
iendothelial nitric oxide syn-
hase (anti-eNOS) (1:50, BD
ransduction Laboratories, Lex-
ngton, Kentucky).
Frozen sections were air-dried,
xed in acetone, and endogenous
eroxidase was block by incuba-
ion with 3% hydrogen peroxide
H2O2). Tissue sections were in-
ubated overnight with primary
ntibodies at 4°C, then with bi-
tinylated anti-mouse immuno-
lobulin (E0354, 1:200 dilution,
AKO) at room temperature for
0 min. The sections were visu-
lized using NiCl2-enhanced
,3=-diaminobenzidine (LY.
86, Dojin Chemical, Kum-
moto, Japan) and counterstained with 0.25% methyl green
r stained with AEC (Nichirei, Tokyo, Japan) without
ounterstaining.
Oil red O staining and immunohistochemistry other than
or CD31 and eNOS were quantified by computer-assisted
mage analysis using NIH-image (1.61). Positive areas are
xpressed as ratios (%) of whole valve leaflet areas. To
uantify endothelial integrity using CD31- and eNOS-
mmunohistochemistry, each positive length on the valve
urface was measured and calculated as a ratio (%) of the
otal circumference of the valve surface using computer
oftware (MCID 4.0, Imaging Research Inc., St. Cather-
nes, Ontario, Canada).
ibonucleic acid (RNA) isolation and real-time reverse
ranscriptional-polymerase chain reaction (RT-PCR).
e assessed valvular gene expression by using RT-PCR.
rozen valve specimens were disrupted in TRIzol reagent
Invitrogen, Carlsbad, California) using a motorized ho-
ogenizer (Microtec Nition, Chiba, Japan). Total RNA
xtracted using the RNeasy Mini Kit (Qiagen, Valencia,
alifornia) was purified and determined spectrophotometri-
ally (ratio 260/280 nm) and by gel electrophoresis. For
everse transcription, complementary deoxyribonucleic acid
DNA) was synthesized from 2 g of total RNA by Avian
yeloblastosis Virus reverse transcriptase using first strand
omplementary DNA synthesis as described in the protocol
upplied with the RT-PCR Kit (Roche Diagnostics, Basel,
witzerland).
The synthesized complementary DNA was quantified by
YBRGreen I dye PCR analysis of each gene using the
ightCycler system according to the manufacturer’s proto-
ol (Roche Diagnostics).
The primers were: core binding factor alpha-1 (Cbfa-1)
orward, 5=-CCGCACGACAACCGCACCAT-3= and
Abbreviations
and Acronyms
ACE  angiotensin-
converting enzyme
ARB  angiotensin
receptor blocker
AS  aortic stenosis
Cbfa-1  core binding
factor alpha-1
DNA  deoxyribonucleic
acid
eNOS  endothelial nitric
oxide synthase
RNA  ribonucleic acid
RT-PCR  reverse
transcriptional-polymerase
chain reaction
TGF  transforming growth
factoreverse, 5=-CGCTCCGGCCCACAAATCTC-3= (289
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orward, 5=-TCACCAGGGCTGCTTTTAAC-3= and
everse, 5=-GCGTTGCTGACAATCTTGAG-3= (397 base
airs). The amount of Cbfa-1 complementary DNA was normal-
zed relative to the respective quantity of glyceraldehyde-3-
hosphate dehydrogenase complementary DNA.
tatistical analysis. Quantitative data are expressed as
eans  SEM. Data were statistically analyzed using an
npaired t-test for parametric data or Mann-Whitney test
or nonparametric data (only for real-time RT-PCR data)
sing a Macintosh computer (Apple, Cupertino, California)
ith StatView software (SAS Institute, Cary, North Caro-
ina. Values of p  0.05 were considered significant.
Figure 1 Olmesartan Inhibits Lesion Formation of the Aortic Va
(A) a, d, g  control; b, e, h  hypercholesterolemic; c, f, i  hypercholesterolem
phage (RAM11) staining; g to i  osteopontin staining. Inset in b shows Oil red O
heads indicate aortic side of valve leaflet. Bar  200 m. Quantitation of Oil red O
olmesartan; Ao  aorta; V  vehicle.esults
erum cholesterol increased in rabbits after 8 weeks on a
igh cholesterol diet from 32.3  9.4 mg/dl in the control
roup (C) to 1,510  265 mg/dl in the vehicle group (V)
nd 2,027  239 mg/dl in the olmesartan group (A). The
ifference in cholesterol levels between A and V groups was
ot statistically significant. Blood pressures were similar for
ll 3 groups (C: 100  7.0/72.7  4.6 mm Hg, V: 100 
.7/75.7 6.0 mm Hg and A: 94.7 11.3/72.35.8 mm Hg;
 NS).
Cholesterol feeding induced lipid accumulation with
acrophage infiltration, especially on the aortic side of the
Hypercholesterolemic Rabbits
esartan treated. a to c  hematoxylin and eosin (H&E) staining; d to f  macro-
ng. Insets in e and h represent positive staining at greater magnification. Arrow-
macrophage (C), and osteopontin (D)-stained areas corrected for total area. A lve in
ic olm
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April 3, 2007:1482–9 ARB Inhibits Atherosclerosis of Aortic Valvealve (Fig. 1A). Olmesartan significantly decreased lipid
eposition (% Oil red O area: V, 11.5  2.1; A, 3.4  0.48;
 0.005) (Fig. 1B) and macrophage accumulation in the
alve leaflet (% RAM-11 area: V, 9.3 0.34; A, 1.4 0.30;
 0.003) (Fig. 1C). Osteopontin, a calcification mediator,
as present at very low levels in control valves (% area in C:
.30  0.34%) but was increased by cholesterol feeding (%
rea in V: 9.0  0.50%). Olmesartan treatment was asso-
iated with a significant decrease in osteopontin (% area in
: 3.6  0.34%, p  0.017 vs. V) (Fig. 1D).
Cholesterol feeding was associated with a significant
ncrease in leaflet ACE immunostaining (p 0.001), which
as substantially blunted with olmesartan (C: 1.7  1.9%,
: 35  17% and A: 9.9  5.4%, p  0.015 vs. V) (Fig. 2).
We next analyzed the endothelial integrity of the aortic
alve in this model. CD31 immunostaining (Fig. 3) showed
hat endothelial integrity was impaired on the aortic surface
f the leaflets after cholesterol feeding (p  0.003), al-
hough it was maintained on the left ventricular surface.
lmesartan significantly reversed this disruption on the
ortic surface of the valve leaflets (C: 66  6.2%, V: 30 
.7% and A: 62  4.8%, p  0.003 vs. V). Figure 4 shows
mmunohistochemical staining for the endothelial marker,
NOS. Because the intensity was similar on both the aortic and
entricular surfaces of the valve leaflets, we analyzed eNOS
Figure 2 Olmesartan Inhibits Up-Regulation of ACE in the Aorti
Angiotensin-converting enzyme (ACE) immunostaining (black) in sections of aortic
treated (C) rabbits. Sections are counterstained with methyl green. Inset in B sho
let. (D) Quantitation of ACE-stained area corrected for total area. Ao  aorta. Barxpression on the whole valve surface. Olmesartan increased
NOS expression as compared with high-cholesterol group (V:
4  5.0 vs. A: 48  5.4%, p  0.008).
The transition from valvular interstitial cells to myofibro-
lasts is a critical change in valvular pathology. We exam-
ned myofibroblasts by immunohistochemical staining using
lpha-smooth muscle actin antibody (Fig. 5). In the control,
how-fed group, alpha-smooth muscle actin-positive myo-
broblasts were sparse and dietary cholesterol obviously
ncreased the alpha-smooth muscle actin-positive area (%
rea C: 0.34  0.13 vs. V: 7.5  2.2; p  0.008).
lmesartan decreased the number of myofibroblasts in the
alve leaflet (% area: 0.34  0.22%, p  0.003 vs. V).
Finally, Cbfa-1 messenger RNA expression was examined
y real-time RT-PCR (Fig. 6). Dietary cholesterol increased,
hereas olmesartan significantly decreased Cbfa-1 mRNA
xpression (analyzed by Mann-Whitney test).
iscussion
he present study demonstrates that the ARB (olmesartan)
nhibits lesion formation in aortic valve leaflets of hyper-
holesterolemic rabbits without significantly altering plasma
holesterol levels or blood pressure. Together with inhibit-
ng the formation of aortic valve lesions, treatment with
ve Induced by Dietary Cholesterol
rom control (A), hypercholesterolemic (B), and hypercholesterolemic olmesartan-
aorta from the same section. Arrowheads indicate aortic side of the valve leaf-
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ARB Inhibits Atherosclerosis of Aortic Valve April 3, 2007:1482–9lmesartan was associated with maintained endothelial in-
egrity and inhibition of the transdifferentiation of valvular
broblasts into myofibroblasts. To our knowledge, this is
he first evidence that a blocker of the renin-angiotensin
ystem can inhibit lesion formation in an animal model of
ortic valve disease.
Others have reported that activation of renin-angiotensin
ystem is involved in the pathogenesis of aortic valve lesions
16,19). These reports indicated that ACE, angiotensin II,
nd the angiotensin II type 1 receptor are upregulated in
iseased aortic valves of humans. The present study showed
hat dietary cholesterol upregulated ACE in the aortic valve,
uggesting that in this rabbit model, originally described by
ajamannan et al. (11,20): 1) activation of the renin-
ngiotensin system is a characteristic of this model, as is the
ase with human aortic valve lesions (16), and 2) blockade of
he renin-angiotensin system inhibits the formation of
esions. The mechanisms by which ARB inhibits lesion
ormation in the aortic valve are not known but may be
imilar to those implicated as antiatherogenic effects, such as
uppressing inflammation (21), inhibiting macrophage ac-
umulation (22), and decreasing oxidative stress (23,24).
In addition, ACE immunostaining was diffusely positive
n the valve leaflets after cholesterol feeding (Fig. 2B),
uggesting that ACE is associated with not only macro-
Figure 3 Olmesartan Preserves Endothelial Integrity of the Aor
CD31 immunostaining of aortic valve endothelium from control (A), hypercholester
is shown as red. Arrowheads indicate aortic side of valve leaflet. (D) Quantitation
Bar  200 m. A  olmesartan; Ao  aorta; C  control; V  vehicle.hages but also low-density lipoprotein particles in extra- mellular matrix such as biglycan and versican, as already
hown in human aortic valves (16). Treatment with ARBs
ecreased ACE expression in the valve leaflets (Fig. 2C).
ne proposed mechanism of this effect is that ARBs can
ecrease extracellular matrix production, which is already
hown in rat myocardial infarct models (25), probably
hrough an inhibition of paracrine release of transforming
rowth factor (TGF)-beta (26). This down-regulation of
xtracellular matrix may lead to decreased retention of
ipoproteins (27), which contain ACE (16), as discussed in
ecent review by O’Brien et al. (28).
Disruption of endothelial integrity may be an important
ontributor to the formation of aortic valve lesions as well as
o the development of atherosclerosis (29). The present
tudy demonstrates, using CD31 immunohistochemistry,
hat the endothelial integrity of the aortic valve is disrupted
n animals fed dietary cholesterol. Interestingly, this disrup-
ion is localized to the aortic, rather than the ventricular,
urface of the aortic valve leaflet. Our findings with CD31
ntibody are consistent with various reports showing that
he aortic side of the aortic valve is more susceptible to
esion formation (30,31). In addition, this study demon-
trates olmesartan not only maintains endothelial integrity
ut also preserves eNOS expression. The mechanisms by
hich ARBs reduce endothelial damage are not known, but
lve
(B), and hypercholesterolemic olmesartan-treated (C) rabbits. Positive staining
31-positive circumference corrected for valve surface (on each side of valve).tic Va
olemic
of CDay be similar to those reported for vascular injury (32).
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April 3, 2007:1482–9 ARB Inhibits Atherosclerosis of Aortic ValveIn addition, olmesartan decreased myofibroblast accumu-
ation in the valve leaflets. Myofibroblasts are believed to
ifferentiate from valvular interstitial cells and TGF-beta is
ritical for this trans-differentiation (33,34). Moreover,
ngiotensin II can stimulate TGF-beta expression in cardiac
yofibroblasts (35). Thus the inhibition of differentiation
nto myofibroblasts in the valve leaflet might be one mech-
nism whereby ARB inhibited lesion formation in the
resent study.
Findings from cell culture (33) and rabbit models (11)
ndicate that myofibroblasts in valve leaflets transdifferenti-
te into osteoblast-like cells. This study confirms that
ietary cholesterol induces the osteoblast-specific transcrip-
ion factor, Cbfa-1 (11), but now also demonstrates that
RB treatment decreases Cbfa-1 expression. This result
onfirms that myofibroblast-osteoblast transition, which is a
ritical pathway in development of calcific valve lesions, is a
omponent of this model but also demonstrates that this
ransdifferentiation is inhibited by ARB treatment.
Rajamannan et al. (11) have demonstrated that statin
nhibits the formation of lesions in the aortic valve of the
abbit model. However, the clinical efficacy of statin therapy
or calcific aortic valves is now controversial. Small, retro-
pective studies have demonstrated a lower rate of progres-
Figure 4 Olmesartan Restores eNOS Expression in the Aortic V
Immunostaining for endothelial nitric oxide synthase (eNOS) in aortic valve from co
rabbits. Positive staining is shown as red. Arrowheads indicate aortic side of valve
face. Ao  aorta. Bar  200 m.ion of AS with statin therapy (6,12–14). However, more tecently, a small, prospective randomized trial showed no
enefit of statin therapy in inhibiting AS progression during
bout a 2-year follow-up (15). These results indicate that, in
he clinical setting, effective statin therapy might require
onger treatment periods or targeting of the disease at an
arlier disease stage, i.e., aortic sclerosis (28). The present
tudy uncovered the first evidence that ARBs are effective
gainst aortic valve lesions in the rabbit model, thus encour-
ging clinical studies of blockers of the renin-angiotensin
ystem in patients with calcific aortic valve disease. One
oncern is that the therapy might target an earlier stage of
isease because we used the same model as Rajamanaan
t al. (11).
Here, we used an ARB to block the renin-angiotensin
ystem. The question now arises as to whether ARBs or
CE-inhibitors are superior in preventing the formation of
ortic valve lesions. Because rabbits do not produce chy-
ase, another angiotensin II synthesizing enzyme, this
odel might not be able to address this issue. However,
ecent data have shown that the expression of chymase as
ell as ACE is increased in the diseased aortic valve in
umans (19), raising the possibility that ARBs have more
otential than ACE inhibitors for preventing AS.
tudy limitations. This study has several limitations. First,
A), hypercholesterolemic (B), and hypercholesterolemic olmesartan-treated (C)
t. (D) Quantitation of eNOS-positive circumference corrected for total valve sur-alve
ntrol (
leaflehe rabbit model in this study is a rapidly progressive model,
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ARB Inhibits Atherosclerosis of Aortic Valve April 3, 2007:1482–9hich is different from degenerative calcific aortic valve in
uman. Therefore, we must be always cautious when we
pply short-time result in animal model to human slowly
rogressive disease, such as atherosclerosis and aortic valve
alcification. Second, the administration of olmesartan
aused a small reduction in systolic blood pressure, though
Figure 5 Olmesartan Decreases the Number of Myofibroblasts
Immunostaining for alpha-smooth muscle actin (black) in sections of aortic valve
treated (C) rabbits. Sections are counterstained with methyl green. Arrowheads in
area corrected for total area. Ao  aorta. Bar  200 m.
Figure 6 Olmesartan Diminishes Cbfa-1
mRNA Expression in the Aortic Valve
Real-time reverse transcriptional polymerase chain reaction of core binding fac-
tor alpha-1 (Cbfa-1) message from aortic valves performed as detailed in the
Methods section (n 12 rabbits per group; *p  0.05). GAPDH  glyceralde-
hyde-3-phosphate dehydrogenase; mRNA  messenger ribonucleic acid.he magnitude of reduction was not statistically significant.
lthough the range of blood pressure was normal and this
ose of olmesartan reportedly does not affect blood pressure
n normotensive rabbits (36), the possibility remains that
his small decrease in blood pressure might affect the
ormation of valve lesions. Further studies are needed to
etermine whether lowering blood pressure with agents
ther than an ARB can inhibit aortic valve lesion formation.
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